{"name":"Gilberto Cruz Arteaga","slug":"gilberto-cruz-arteaga","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Azithromycin / Ivermectin / Ribaroxaban / Paracetamol","genericName":"Azithromycin / Ivermectin / Ribaroxaban / Paracetamol","slug":"azithromycin-ivermectin-ribaroxaban-paracetamol","indication":"Unknown — this combination is highly unusual and not a recognized marketed or standard pipeline product","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Azithromycin / Ribaroxaban / Paracetamol","genericName":"Azithromycin / Ribaroxaban / Paracetamol","slug":"azithromycin-ribaroxaban-paracetamol","indication":"Infection with concurrent thrombotic risk requiring anticoagulation and symptom management (indication not clearly defined in public literature)","status":"phase_3"}]}],"pipeline":[{"name":"Azithromycin / Ivermectin / Ribaroxaban / Paracetamol","genericName":"Azithromycin / Ivermectin / Ribaroxaban / Paracetamol","slug":"azithromycin-ivermectin-ribaroxaban-paracetamol","phase":"phase_3","mechanism":"This is a fixed-dose combination of four active ingredients with distinct mechanisms: azithromycin inhibits bacterial protein synthesis, ivermectin paralyzes parasites, rivaroxaban inhibits factor Xa in the coagulation cascade, and paracetamol reduces pain and fever through central nervous system effects.","indications":["Unknown — this combination is highly unusual and not a recognized marketed or standard pipeline product"],"catalyst":""},{"name":"Azithromycin / Ribaroxaban / Paracetamol","genericName":"Azithromycin / Ribaroxaban / Paracetamol","slug":"azithromycin-ribaroxaban-paracetamol","phase":"phase_3","mechanism":"This is a fixed-dose combination of three drugs: azithromycin (a macrolide antibiotic), rivaroxaban (an anticoagulant), and paracetamol (an analgesic/antipyretic) that work through distinct mechanisms.","indications":["Infection with concurrent thrombotic risk requiring anticoagulation and symptom management (indication not clearly defined in public literature)"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}